Company intelligence / Profile preview

NeuroServo

Montreal, Quebec, Canadaneuroservo.com ↗

Ownership: Private
Development stage: Commercial

Overview

The VEEGix portable EEG system has demonstrated clinical equivalence to established predicate devices for real-time brainwave analysis. It enables rapid, objective neurological assessment at the point of care. Clinical studies have shown comparable signal quality to standard hospital systems, supporting its use for seizure and delirium detection. The device received Health Canada approval in September 2021 and FDA Class II clearance in August 2024.

Used by multiple intensive care units; pilot studies ongoing for pediatric neurodevelopmental disorders.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapy (EEG monitoring)
Industry: Physiological Monitoring

Partnerships

Mayo Clinic collaboration agreement signed in 2022

Beyond the preview

Go deeper on NeuroServo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroServo.

Explore the full profile